Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01129778 · ClinicalTrials.gov registry record · NA
Assessment of Zegerid on Esophageal pH in Patients With Barrett's Esophagus
A NA study, sponsored by Stanford University.
- Terminated
- Registry status
- NA
- Development phase
- 27
- Enrollment target
NCT01129778: Clinical Trial NA study, sponsored by Stanford University.
NCT01129778 is a NA study that was terminated before completion, run by Stanford University. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01129778, a NA study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this research study is to assess how safe, effective (how well it works), and tolerable (to put up with) the drug Zegerid is in reducing reflux episodes in patients who have both gastroesophageal reflux disease (GERD) and Barrett's esophagus. Zegerid has been approved by the US Food and Drug Administration (FDA) for the treatment of GERD. The investigators hope to learn the effectiveness of Zegerid for reducing the amount of acid reflux patients are experiencing in the esophagus (swallowing pipe).
Interventions
- DRUG Zegerid (proton pump inhibitor)
- PROCEDURE Bravo pH monitoring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2009-11 |
| Est. Completion | 2010-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01129778
The ClinicalTrials.gov registry entry for NCT01129778 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Zegerid (proton pump inhibitor) is the first listed.
NCT01129778 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01129778 about?
NCT01129778 is a clinical study titled "Assessment of Zegerid on Esophageal pH in Patients With Barrett's Esophagus". The purpose of this research study is to assess how safe, effective (how well it works), and tolerable (to put up with) the drug Zegerid is in reducing reflux episodes in patients who have both gastroesophageal reflux disease (GERD) and Barrett's esophagus. Zegerid has been approved by the US Food a...
What is the current status of trial NCT01129778?
This trial is currently terminated. It is a NA study. The enrollment target is 27 participants. The study started on 2009-11. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01129778?
The interventions under investigation include: Zegerid (proton pump inhibitor) (DRUG), Bravo pH monitoring (PROCEDURE).
Who is sponsoring clinical trial NCT01129778?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.